Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

UFS to host one of three world summits on crystallography
2014-04-15

 
Prof André Roodt from the Department of Chemistry at the University of the Free State (UFS), co-unveiled a special plaque in Poznan, Poland, as president of the European Crystallographic Association, with prof Gautam Desiraju, president of the IUCr (front right) and others to commemorate the Nobel prize winner Max von Laue. (Photo's: Milosz Ruszkowski, Grzegorz Dutkiewicz)

Prof André Roodt from the Department of Chemistry at the University of the Free State (UFS), co-unveiled a special plaque in Poznan, Poland, as president of the European Crystallographic Association, to commemorate the Nobel prize winner Max von Laue at a special Laue Symposium organised by prof Mariusz Jaskolski from the A. Mickiewicz University in Poznan.

Max von Laue, who spent his early childhood in Poznan, was the first scientist to diffract X-rays with a crystal.

2014 has been declared by the United Nations as the International Year of Crystallography, and it was recently officially opened at the UNESCO headquarters in Paris, France, by the Secretary-General of the UN, Ban Ki-moon. The International Year of Crystallography celebrates the centennial of the work of Max von Laue and the father and son, William Henry and William Laurence Bragg.

As part of the celebrations, Prof Roodt, president of the European Crystallographic Association, one of the three regional affiliates (Americas, Europe and Africa; Asia and Australasia) of the International Union of Crystallography (IUCr), was invited by the president of the IUCr, Prof Gautam Desiraju, to host one of the three world summits, wherein crystallography is to showcase its achievements and strategise for the future.

The summit and conference will take place on the Bloemfontein Campus of the UFS from 12 to 17 October 2014 and is titled: 'Crystallography as vehicle to promote science in Africa and beyond.' It is an ambitious meeting wherein it is anticipated to bring the French-, English- and Arab-speaking nations of Africa together to strategise how science can be expanded, and to offer possibilities for this as nestled in crystallography. Young and established scientists, and politicians associated with science and science management, are the target audience to be brought together in Bloemfontein.

Dr Thomas Auf der Heyde, acting Director General of the South African Department of Science and Technology (DST), has committed some R500 000 for this effort, while the International Union of Crystallography provided R170 000.

“Crystals and crystallography form an integrated part of our daily lives, form bones and teeth, to medicines and viruses, new catalysts, jewellery, colour pigments, chocolates, electronics, batteries, metal blades in airplane turbines, panels for solar energy and many more. In spite of this, unfortunately, not many people know much about X-ray crystallography, although it is probably one of the greatest innovations of the twentieth century. Determining the structure of the DNA was one of the most significant scientific events of the 20th century. It has helped understand how genetic messages are being passed on between cells inside our body – everything from the way instructions are sent to proteins to fight infections, to how life is reproduced.

“At the UFS, crystallography finds application in Chemistry, Physics, Biology, Mathematics, Geology, Engineering and the Medical fields. Crystallography is used by the Curiosity Rover, analysing the substances and minerals on Mars!

“The UFS’s Departments of Chemistry and Physics, in particular, have advanced instruments and important research thrusts wherein X-ray crystallography has formed a central part for more than 40 years.

“Crystallography has produced some 28 Nobel prize winners over the past 100 years and continues to provide the means for fundamental and applied research,” said Prof Roodt.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept